A similar increase in PSA-NCAM immunolabeling was recently reported in pilocarpine-treated mice [44], kainic-acid treated rodents [45]; [46] and animals exposed to the amygdala kindling model of epilepsy [47]. This evidence concerns the gene NCAM1 and epilepsy.